Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?

Cohen JT, Silver MC, Ollendorf DA, Neumann PJ.

Value Health. 2019 Dec;22(12):1396-1401. doi: 10.1016/j.jval.2019.08.003. Epub 2019 Oct 7.

PMID:
31806196
2.

Cost-Effectiveness Analysis in Pediatric Imaging: The Evidence (or Lack Thereof) Thus Far.

Otero HJ, Degnan AJ, Kadom N, Neumann PJ, Lavelle TA.

J Am Coll Radiol. 2019 Nov 29. pii: S1546-1440(19)31196-2. doi: 10.1016/j.jacr.2019.10.005. [Epub ahead of print]

PMID:
31790678
3.

Comparative Modeling to Inform Health Policy Decisions: A Step Forward.

Kim DD, Neumann PJ.

Ann Intern Med. 2019 Nov 5. doi: 10.7326/M19-2797. [Epub ahead of print] No abstract available.

PMID:
31683277
4.

Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug Coverage.

Chambers JD, Panzer AD, Pope EF, Graff JS, Neumann PJ.

Health Aff (Millwood). 2019 Nov;38(11):1882-1886. doi: 10.1377/hlthaff.2019.00201.

PMID:
31682500
5.

Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy.

Garrison LP Jr, Neumann PJ, Willke RJ.

J Manag Care Spec Pharm. 2019 Nov;25(11):1185-1192. doi: 10.18553/jmcp.2019.25.11.1185.

6.

Variation in US private health plans' coverage of orphan drugs.

Chambers JD, Panzer AD, Kim DD, Margaretos NM, Neumann PJ.

Am J Manag Care. 2019 Oct;25(10):508-512.

7.

Yes, Improve the US Value Frameworks, But Recognize They Are Already in Prime Time.

Neumann PJ.

Value Health. 2019 Sep;22(9):975-976. doi: 10.1016/j.jval.2019.04.1929. Epub 2019 Jul 26. No abstract available.

PMID:
31511185
8.

Embracing the science of value in health.

Krahn M, Bryan S, Lee K, Neumann PJ.

CMAJ. 2019 Jul 2;191(26):E733-E736. doi: 10.1503/cmaj.181606. No abstract available.

PMID:
31266787
9.

Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics Authors.

Emerson J, Bacon R, Kent A, Neumann PJ, Cohen JT.

Pharmacoeconomics. 2019 Nov;37(11):1411. doi: 10.1007/s40273-019-00813-5.

10.

Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy.

Drummond MF, Neumann PJ, Sullivan SD, Fricke FU, Tunis S, Dabbous O, Toumi M.

Value Health. 2019 Jun;22(6):661-668. doi: 10.1016/j.jval.2019.03.012. Epub 2019 May 17.

PMID:
31198183
11.

Taking stock of cost-effectiveness analysis of healthcare in China.

Butt T, Liu GG, Kim DD, Neumann PJ.

BMJ Glob Health. 2019 May 14;4(3):e001418. doi: 10.1136/bmjgh-2019-001418. eCollection 2019.

12.

Publication of Decision Model Source Code: Attitudes of Health Economics Authors.

Emerson J, Bacon R, Kent A, Neumann PJ, Cohen JT.

Pharmacoeconomics. 2019 Nov;37(11):1409-1410. doi: 10.1007/s40273-019-00796-3. No abstract available. Erratum in: Pharmacoeconomics. 2019 Jun 19;:.

13.

Adherence to the iDSI reference case among published cost-per-DALY averted studies.

Emerson J, Panzer A, Cohen JT, Chalkidou K, Teerawattananon Y, Sculpher M, Wilkinson T, Walker D, Neumann PJ, Kim DD.

PLoS One. 2019 May 1;14(5):e0205633. doi: 10.1371/journal.pone.0205633. eCollection 2019.

14.

Cost-Effectiveness Studies in the ICU: A Systematic Review.

Wilcox ME, Vaughan K, Chong CAKY, Neumann PJ, Bell CM.

Crit Care Med. 2019 Aug;47(8):1011-1017. doi: 10.1097/CCM.0000000000003768.

PMID:
30985446
15.

Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.

Lin PJ, D'Cruz B, Leech AA, Neumann PJ, Sanon Aigbogun M, Oberdhan D, Lavelle TA.

Pharmacoeconomics. 2019 Apr;37(4):597-608. doi: 10.1007/s40273-019-00788-3.

PMID:
30903567
16.

Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency.

Kim DD, Cohen JT, Wong JB, Mohit B, Fendrick AM, Kent DM, Neumann PJ.

Health Aff (Millwood). 2019 Jan;38(1):60-67. doi: 10.1377/hlthaff.2018.05148.

PMID:
30615528
17.

Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies.

Chambers JD, Pope EF, Wilkinson CL, Neumann PJ.

J Manag Care Spec Pharm. 2018 Dec;24(12):1240-1246. doi: 10.18553/jmcp.2018.24.12.1240.

18.

Understanding and improving value frameworks with real-world patient outcomes.

Jena AB, Chou JW, Yoon L, Aubry WM, Berger J, Burton W, Fendrick AM, Fick DM, Franklin D, Killion R, Lakdawalla DN, Neumann PJ, Patel K, Yee J, Sakurada B, Yu-Isenberg K.

Am J Manag Care. 2018 Nov;24(11):506-509.

19.

Future Directions for Cost-effectiveness Analyses in Health and Medicine.

Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, Owens DK, Meltzer DO, Kuntz KM, Krahn M, Feeny D, Basu A, Russell LB, Siegel JE, Ganiats TG, Sanders GD.

Med Decis Making. 2018 Oct;38(7):767-777. doi: 10.1177/0272989X18798833.

PMID:
30248277
20.

Risk-Targeted Lung Cancer Screening.

Kumar V, Cohen JT, Neumann PJ, Kent DM.

Ann Intern Med. 2018 Aug 7;169(3):200-201. doi: 10.7326/L18-0237. No abstract available.

PMID:
30083710
21.

Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies.

Leech AA, Kim DD, Cohen JT, Neumann PJ.

Value Health. 2018 Jul;21(7):759-761. doi: 10.1016/j.jval.2017.12.016. Epub 2018 Feb 21.

22.

Specialty Drug Coverage Varies Across Commercial Health Plans In The US.

Chambers JD, Kim DD, Pope EF, Graff JS, Wilkinson CL, Neumann PJ.

Health Aff (Millwood). 2018 Jul;37(7):1041-1047. doi: 10.1377/hlthaff.2017.1553.

PMID:
29985695
23.

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.

Thorat T, Neumann PJ, Chambers JD.

J Manag Care Spec Pharm. 2018 Jul;24(7):632-642. doi: 10.18553/jmcp.2018.24.7.632. Review.

24.

QALYs in 2018-Advantages and Concerns.

Neumann PJ, Cohen JT.

JAMA. 2018 Jun 26;319(24):2473-2474. doi: 10.1001/jama.2018.6072. No abstract available.

PMID:
29800152
25.

A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures.

Chambers J, Pope E, Bungay K, Cohen J, Ciarametaro M, Dubois R, Neumann PJ.

Value Health. 2018 Apr;21(4):400-406. doi: 10.1016/j.jval.2017.10.007. Epub 2017 Dec 6.

26.

Insurance coverage for genomic tests.

Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP Jr, Douglas MP, Weldon CB.

Science. 2018 Apr 20;360(6386):278-279. doi: 10.1126/science.aas9268. Epub 2018 Apr 19. No abstract available.

27.

Cost comparison across heart failure patients with reduced and preserved ejection fractions: Analyses of inpatient decompensated heart failure admissions.

Olchanski N, Vest AR, Cohen JT, Neumann PJ, DeNofrio D.

Int J Cardiol. 2018 Jun 15;261:103-108. doi: 10.1016/j.ijcard.2018.03.024.

PMID:
29657034
28.

A Call for Open-Source Cost-Effectiveness Analysis.

Cohen JT, Neumann PJ, Wong JB.

Ann Intern Med. 2018 Apr 3;168(7):529. doi: 10.7326/L17-0695. No abstract available.

PMID:
29610903
29.

Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients.

Zhong Y, Valderrama A, Yao J, Donga P, Bilir P, Neumann PJ.

Value Health. 2018 Mar;21(3):304-309. doi: 10.1016/j.jval.2017.02.008. Epub 2017 Sep 21.

30.

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value.

Olchanski N, Hansen RN, Pope E, D'Cruz B, Fergie J, Goldstein M, Krilov LR, McLaurin KK, Nabrit-Stephens B, Oster G, Schaecher K, Shaya FT, Neumann PJ, Sullivan SD.

Open Forum Infect Dis. 2018 Feb 7;5(3):ofy031. doi: 10.1093/ofid/ofy031. eCollection 2018 Mar. Review.

31.

Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures.

Neumann PJ, Anderson JE, Panzer AD, Pope EF, D'Cruz BN, Kim DD, Cohen JT.

Version 2. Gates Open Res. 2018 Mar 5 [revised 2018 Jan 1];2:5. doi: 10.12688/gatesopenres.12786.2. eCollection 2018.

32.

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].

Garrison LP Jr, Neumann PJ, Willke RJ, Basu A, Danzon PM, Doshi JA, Drummond MF, Lakdawalla DN, Pauly MV, Phelps CE, Ramsey SD, Towse A, Weinstein MC.

Value Health. 2018 Feb;21(2):161-165. doi: 10.1016/j.jval.2017.12.009.

33.

Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].

Willke RJ, Neumann PJ, Garrison LP Jr, Ramsey SD.

Value Health. 2018 Feb;21(2):155-160. doi: 10.1016/j.jval.2017.12.011.

34.

An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].

Garrison LP Jr, Pauly MV, Willke RJ, Neumann PJ.

Value Health. 2018 Feb;21(2):124-130. doi: 10.1016/j.jval.2017.12.006.

35.

A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].

Neumann PJ, Willke RJ, Garrison LP Jr.

Value Health. 2018 Feb;21(2):119-123. doi: 10.1016/j.jval.2017.12.012.

36.

Patient Variability Seldom Assessed in Cost-effectiveness Studies.

Lavelle TA, Kent DM, Lundquist CM, Thorat T, Cohen JT, Wong JB, Olchanski N, Neumann PJ.

Med Decis Making. 2018 May;38(4):487-494. doi: 10.1177/0272989X17746989. Epub 2018 Jan 19. Review.

37.

Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.

Kumar V, Cohen JT, van Klaveren D, Soeteman DI, Wong JB, Neumann PJ, Kent DM.

Ann Intern Med. 2018 Feb 6;168(3):161-169. doi: 10.7326/M17-1401. Epub 2018 Jan 2.

38.

Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among Medicare beneficiaries with Alzheimer's disease.

Lin PJ, Zhong Y, Fillit HM, Cohen JT, Neumann PJ.

Alzheimers Dement. 2017 Oct;13(10):1174-1178. doi: 10.1016/j.jalz.2017.08.010. Epub 2017 Sep 5.

PMID:
28886338
39.

A Call for Open-Source Cost-Effectiveness Analysis.

Cohen JT, Neumann PJ, Wong JB.

Ann Intern Med. 2017 Sep 19;167(6):432-433. doi: 10.7326/M17-1153. Epub 2017 Aug 29. No abstract available.

PMID:
28847014
40.

ICER's Revised Value Assessment Framework for 2017-2019: A Critique.

Neumann PJ, Cohen JT.

Pharmacoeconomics. 2017 Oct;35(10):977-980. doi: 10.1007/s40273-017-0560-y. No abstract available.

PMID:
28791663
41.

Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process.

Chambers JD, Thorat T, Wilkinson CL, Neumann PJ.

Health Aff (Millwood). 2017 Aug 1;36(8):1408-1415. doi: 10.1377/hlthaff.2016.1541.

PMID:
28784733
42.

A Review of Empirical Analyses of Disinvestment Initiatives.

Chambers JD, Salem MN, D'Cruz BN, Subedi P, Kamal-Bahl SJ, Neumann PJ.

Value Health. 2017 Jul - Aug;20(7):909-918. doi: 10.1016/j.jval.2017.03.015. Epub 2017 May 16. Review.

43.

The influence of time horizon on results of cost-effectiveness analyses.

Kim DD, Wilkinson CL, Pope EF, Chambers JD, Cohen JT, Neumann PJ.

Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):615-623. doi: 10.1080/14737167.2017.1331432. Epub 2017 May 23.

PMID:
28504026
44.

Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models.

Olchanski N, Cohen JT, Neumann PJ, Wong JB, Kent DM.

Med Decis Making. 2017 Oct;37(7):790-801. doi: 10.1177/0272989X17704855. Epub 2017 Apr 11.

45.

Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks.

Cohen JT, Anderson JE, Neumann PJ.

Value Health. 2017 Feb;20(2):193-199. doi: 10.1016/j.jval.2016.11.012.

46.

Cost-Effectiveness Analysis 2.0.

Neumann PJ, Sanders GD.

N Engl J Med. 2017 Jan 19;376(3):203-205. doi: 10.1056/NEJMp1612619. No abstract available.

PMID:
28099837
47.

Updated Recommendations for Cost-effectiveness Studies-Reply.

Sanders GD, Neumann PJ, Russell LB.

JAMA. 2017 Jan 3;317(1):90. doi: 10.1001/jama.2016.17839. No abstract available.

PMID:
28030697
48.

A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted.

Neumann PJ, Thorat T, Zhong Y, Anderson J, Farquhar M, Salem M, Sandberg E, Saret CJ, Wilkinson C, Cohen JT.

PLoS One. 2016 Dec 22;11(12):e0168512. doi: 10.1371/journal.pone.0168512. eCollection 2016. Review.

49.

The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh.

Teerawattananon Y, Tantivess S, Yamabhai I, Tritasavit N, Walker DG, Cohen JT, Neumann PJ.

Health Res Policy Syst. 2016 Dec 3;14(1):86.

50.

Cost-Effectiveness Analysis Expands its Reach Worldwide.

Greenberg D, Neumann PJ.

Value Health Reg Issues. 2016 Sep;10:101-102. doi: 10.1016/j.vhri.2016.10.001. Epub 2016 Nov 12. No abstract available.

PMID:
27881271

Supplemental Content

Loading ...
Support Center